Clinical Trial Update: A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) [Phase 3]

View source ↗

Summary

A randomized, double-blind, placebo-controlled Phase III trial evaluating tivantinib (ARQ-197) in hepatocellular carcinoma has completed in Japan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ARQ 197 (tivantinib) (tivantinib)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Liver Cancer | Phase 3 | Status: COMPLETED